Longitudinal evaluation of adherence, retention, and transition patterns of adolescents living with HIV in Nigeria.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 19 12 2019
accepted: 14 07 2020
entrez: 1 8 2020
pubmed: 1 8 2020
medline: 30 9 2020
Statut: epublish

Résumé

Adherence to antiretroviral therapy (ART) and retention in treatment programs are required for successful virologic suppression and treatment outcomes. As the number of adolescents living with HIV continues to increase globally, more information about adherence and retention patterns during and through transition from child- to adult-centered care is needed to ensure provision of a high level of care and inform development of targeted interventions to improve patient outcomes in this vulnerable population. In this analysis, we sought to describe long-term trends in adherence, retention, and virologic suppression in adolescents receiving ART at a pediatric HIV clinic in Nigeria through transition to the adult clinic. The Jos University Teaching Hospital, United States President's Emergency Plan for AIDS Relief (PEPFAR)-funded HIV clinic in Jos, Plateau State, Nigeria. We conducted a retrospective observational longitudinal evaluation of data that had been collected during the course of care in a large pediatric ART program in Nigeria. We used descriptive statistics to define our patient population and quantify retention from ART initiation through adolescence and transition to adult-centered care. Logistic regression was used to evaluate predictors of loss to follow-up. We used medication possession ratio (MPR) to quantify adherence for each year a patient was on ART. To evaluate adherence and virologic suppression, we measured the proportion of patients with ≥95% MPR and the proportion with virologic suppression (viral load ≤400 copies/mL) within each age cohort, and used bivariate analyses to examine any association between MPR and VL suppression for all person-years observed. A total of 476 patients received at least one dose of ART as an adolescent (ages 10-19 years). The proportions of patients lost to follow-up were: 11.9% (71/597) prior to adolescence, 19.1% (31/162) during adolescence, and 13.7% (10/73) during transition to adult-centered care. While over 80% of patients had ≥95% medication adherence in all age groups, their viral load suppression rates through adolescence and post-transition were only 55.6%-64.0%. For patients that successfully transitioned to adult-centered care, we observed 87.7% (50/57) retention at month 12 post-transition, but only 34.6% (9/26) viral load suppression. Our evaluation found considerable proportions of adolescents lost to follow-up throughout the ART program cascade. We also found discrepancies between the proportions of patients with ≥95% MPR and the proportions with VL suppression, suggesting that true medication adherence in this population may be poor. Significant attention and targeted interventions to improve retention and adherence focused on adolescents are needed in order for global programs to achieve 90-90-90 goals.

Identifiants

pubmed: 32735566
doi: 10.1371/journal.pone.0236801
pii: PONE-D-19-35189
pmc: PMC7394430
doi:

Substances chimiques

Anti-HIV Agents 0

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0236801

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Clin Infect Dis. 2006 Oct 1;43(7):939-41
pubmed: 16941380
J Int AIDS Soc. 2015 Dec 02;18(Suppl 6):20257
pubmed: 26639113
Curr HIV Res. 2015;13(3):210-8
pubmed: 25986372
PLoS One. 2018 Jun 12;13(6):e0198802
pubmed: 29894519
Lancet. 2006 Nov 4;368(9547):1587-94
pubmed: 17084759
Afr J Reprod Health. 2013 Dec;17(4 Spec No):17-31
pubmed: 24689314
Arch Dis Child. 2011 Jun;96(6):548-53
pubmed: 21388969
Soc Work Health Care. 2007;46(1):1-19
pubmed: 18032153
Pediatrics. 2011 Oct;128(4):762-71
pubmed: 21930548
PLoS One. 2014 Jun 03;9(6):e99061
pubmed: 24893160
AIDS Patient Care STDS. 2011 Jul;25(7):413-22
pubmed: 21992620
JAMA. 2006 Aug 9;296(6):679-90
pubmed: 16896111
Biomed Res Int. 2019 Dec 2;2019:9623159
pubmed: 31886271
J Pediatr. 2011 Nov;159(5):714-9
pubmed: 21868035
J Int AIDS Soc. 2013 Jun 18;16:18650
pubmed: 23782484
Top HIV Med. 2009 Feb-Mar;17(1):14-25
pubmed: 19270345
AIDS Res Hum Retroviruses. 2013 Jun;29(6):892-900
pubmed: 23373540
AIDS Patient Care STDS. 2011 Aug;25(8):465-73
pubmed: 21745141
Lancet Infect Dis. 2014 Jul;14(7):627-39
pubmed: 24406145
J Int AIDS Soc. 2017 May 16;20(Suppl 3):21528
pubmed: 28530039
AIDS Behav. 2013 Jan;17(1):86-93
pubmed: 23142855
PLoS One. 2013;8(4):e60073
pubmed: 23573232
AIDS Behav. 2019 Sep;23(9):2498-2513
pubmed: 31377893
AIDS Res Hum Retroviruses. 2008 Aug;24(8):1031-5
pubmed: 18724803
AIDS Patient Care STDS. 2014 Jul;28(7):381-93
pubmed: 24749770
AIDS Patient Care STDS. 2008 Dec;22(12):977-87
pubmed: 19072104
J Adolesc Health. 2015 Mar;56(3):345-51
pubmed: 25703322
AIDS Patient Care STDS. 2013 Dec;27(12):692-6
pubmed: 24073595
J Acquir Immune Defic Syndr. 2000 Apr 1;23(4):360-1
pubmed: 10836763
Future Virol. 2015;9(10):921-929
pubmed: 25983853
Lancet Child Adolesc Health. 2018 Mar;2(3):214-222
pubmed: 30169256
J Adolesc Health. 2011 May;48(5):429-40
pubmed: 21501800
AIDS Care. 2010 Aug;22(8):970-8
pubmed: 20229370
Cochrane Database Syst Rev. 2011 Dec 07;(12):CD009513
pubmed: 22161452
PLoS One. 2016 Oct 20;11(10):e0164030
pubmed: 27764094
Curr Opin HIV AIDS. 2018 May;13(3):236-248
pubmed: 29528851
J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):542-545
pubmed: 26990822
Int J Med Inform. 2015 Jan;84(1):58-68
pubmed: 25301692
AIDS. 2013 Nov;27 Suppl 2:S207-13
pubmed: 24361630
J Acquir Immune Defic Syndr. 2014 Jul 1;66 Suppl 2:S144-53
pubmed: 24918590
J Acquir Immune Defic Syndr. 2006 Sep;43(1):78-84
pubmed: 16878045
Annu Rev Med. 2010;61:169-85
pubmed: 19622036
Pediatrics. 2014 Mar;133(3):558-62
pubmed: 24567016
Bull World Health Organ. 2019 Dec 1;97(12):837-845
pubmed: 31819292
Arch Pediatr Adolesc Med. 2005 Aug;159(8):764-70
pubmed: 16061785
Trials. 2017 Dec 14;18(1):595
pubmed: 29237487

Auteurs

Seema T Meloni (ST)

Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.

Patricia Agaba (P)

Department of Family Medicine, University of Jos and Jos University Teaching Hospital, Jos, Nigeria.

Charlotte A Chang (CA)

Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.

Esther Yiltok (E)

Department of Pediatrics, University of Jos and Jos University Teaching Hospital, Jos, Nigeria.

Stephen Oguche (S)

Department of Pediatrics, University of Jos and Jos University Teaching Hospital, Jos, Nigeria.

Emeka Ejeliogu (E)

Department of Pediatrics, University of Jos and Jos University Teaching Hospital, Jos, Nigeria.

Oche Agbaji (O)

Department of Medicine, University of Jos and Jos University Teaching Hospital, Jos, Nigeria.

Prosper Okonkwo (P)

APIN Public Health Initiatives, Ltd./Gte., Abuja, Nigeria.

Phyllis J Kanki (PJ)

Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH